Loading
A phase 2 trial of Cadonilimab, Paclitaxel / nab-paclitaxel in vulvar cancer, run by Akeso, now recruiting.
AK104 for Recurrent or Metastatic Vulvar Cancer is a phase 2 interventional study registered as NCT05932212 by Akeso, with 20 participants planned, started 2023-08-25 and due to reach its primary completion in 2025-12-15. Interventions recorded: AK104, AK104+ Paclitaxel+Cisplatin or Carboplatin. Conditions listed: Vulvar Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Cadonilimab, Akeso, Bispecific antibodies, Paclitaxel / nab-paclitaxel.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Cadonilimab, Akeso, Bispecific antibodies, Paclitaxel / nab-paclitaxel.
Shares HPV-independent vulvar squamous cell carcinoma (p53-mutant), HPV-associated vulvar squamous cell carcinoma, Vulvar cancer, Immune checkpoint inhibitors.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Cadonilimab, Akeso, Bispecific antibodies, Paclitaxel / nab-paclitaxel.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/